Pfizer (PFE) Says Positive Data On Aromasin and Ellence Will Be Presented at San Antonio Breast Cancer Symposium
More News related to PFE
- Paladin Reports Record Third Quarter 2009 Financial Results
- Pfizer Merger to Shut Down Six R&D Sites, Resulting in 2,000 Layoffs, an Industrial Info News Alert
- Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
- Former Pfizer Global R&D President John LaMattina Joins PureTech Ventures as Senior Partner; PureTech Announces Partner Promotions
- Monsanto (MON) Agrees to Acquire Pfizer's (PFE) Chesterfield Village Research Center for $435M
More News related to FDA
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Results of two studies evaluating the hormonal therapy Aromasin and the chemotherapy Ellence will be presented at the San Antonio Breast Cancer Symposium December 14 - 17, 2006. In addition, Pfizer (NYSE: PFE) announced the initiation of a phase III clinical trial to study Sutent in patients with advanced (or metastatic) breast cancer -- cancer that originated in the breast and has spread to other parts of the body.
"New data are showing that Aromasin and Ellence can improve the outcomes for women with breast cancer," said Dr. Charles Baum, vice president of Pfizer Global Research and Development and oncology clinical leader. "Looking forward, we are pleased to begin studying patients with Sutent in combination with a taxane in a Phase III trial for the first-line treatment of advanced breast cancer."
Related Categories
FDAStocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
